Experimental combo aims to boost immune attack on tough melanoma
NCT ID NCT05089370
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether adding an oral drug (decitabine/cedazuridine) to the immunotherapy nivolumab can help the immune system better fight mucosal melanoma, a rare and aggressive skin cancer. The study includes 8 adults with advanced disease that cannot be surgically removed. Researchers are primarily checking safety and the right dose, while also looking for signs of tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Decitabine/cedazuridine (DEC-C) combined with nivolumab
What this could lead to
If successful, this combination could offer a new treatment option for mucosal melanoma, a rare and hard-to-treat skin cancer.
What could go wrong
This is a very small, early-phase trial with only 8 participants, so results may not apply broadly. The combination may cause side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Colorado Hospital
Aurora, Colorado, 80045, United States